Lexington, MA-based Cubist Pharmaceuticals announced it will pay $4.7 million, plus another $1 million in research and operating costs, for an exclusive option to buy Seattle’s Illumigen Biosciences. Illumigen’s lead compound is a protein-based treatment for hepatitis C. If Cubist exercises its option it will pay $9 million upfront, plus development and regulatory milestone payments that could surpass $330 million.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
